NASDAQ:PSNL

Personalis Stock Forecast, Price & News

$22.19
-1.19 (-5.09 %)
(As of 04/16/2021 12:00 AM ET)
Add
Compare
Today's Range
$21.75
Now: $22.19
$23.50
50-Day Range
$20.71
MA: $25.16
$32.51
52-Week Range
$8.30
Now: $22.19
$53.46
Volume549,565 shs
Average Volume1.06 million shs
Market Capitalization$971.26 million
P/E RatioN/A
Dividend YieldN/A
Beta1.71
Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies. It offers NeXT Platform, which provides data for cancer therapy development, personalized therapies, therapy selection, and diagnostics. The company also provides a complementary liquid biopsy assay that analyzes various human genes versus. It serves biopharmaceutical customers, universities and non-profits, diagnostics companies, and government entities. The company has partnership with Berry Genomics; and Natera, Inc. Personalis, Inc. was founded in 2011 and is headquartered in Menlo Park, California.
Personalis logo

Industry, Sector and Symbol

Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PSNL
CUSIPN/A
CIKN/A
Phone650-752-1300
Employees234
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$65.21 million
Book Value$3.42 per share

Profitability

Net Income$-25,080,000.00

Miscellaneous

Market Cap$971.26 million
Next Earnings Date5/6/2021 (Estimated)
OptionableNot Optionable

Headlines

Oppenheimer Reaffirms Hold Rating for Personalis (NASDAQ:PSNL)
April 14, 2021 |  americanbankingnews.com
Making the Best of the Peculiar Market Action - RealMoney
April 9, 2021 |  realmoney.thestreet.com
Personalis (NASDAQ:PSNL) Trading Down 8%
April 7, 2021 |  americanbankingnews.com
Personalis (NASDAQ:PSNL) Shares Gap Up to $24.13
April 5, 2021 |  americanbankingnews.com
Personalis (NASDAQ:PSNL) Trading Up 6.2%
March 30, 2021 |  americanbankingnews.com
Personalis (NASDAQ:PSNL) Trading Down 6.4%
March 29, 2021 |  americanbankingnews.com
Personalis (NASDAQ:PSNL) Shares Gap Down to $21.94
March 25, 2021 |  americanbankingnews.com
Personalis Announces Changes to its Board of Directors
March 8, 2021 |  finance.yahoo.com
4 SPACs for the Future - Motley Fool
March 7, 2021 |  fool.com
See More Headlines

MarketRank

Overall MarketRank

1.55 out of 5 stars

Medical Sector

451st out of 2,024 stocks

Medical Laboratories Industry

7th out of 39 stocks

Analyst Opinion: 3.4Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
$22.19
-1.19 (-5.09 %)
(As of 04/16/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive PSNL News and Ratings via Email

Sign-up to receive the latest news and ratings for PSNL and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Personalis (NASDAQ:PSNL) Frequently Asked Questions

Is Personalis a buy right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Personalis in the last twelve months. There are currently 2 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Personalis stock.
View analyst ratings for Personalis
or view top-rated stocks.

What stocks does MarketBeat like better than Personalis?

Wall Street analysts have given Personalis a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Personalis wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Personalis?

Personalis saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 3,060,000 shares, an increase of 34.2% from the February 28th total of 2,280,000 shares. Based on an average trading volume of 1,100,000 shares, the days-to-cover ratio is presently 2.8 days.
View Personalis' Short Interest
.

When is Personalis' next earnings date?

Personalis is scheduled to release its next quarterly earnings announcement on Thursday, May 6th 2021.
View our earnings forecast for Personalis
.

How were Personalis' earnings last quarter?

Personalis, Inc. (NASDAQ:PSNL) released its earnings results on Thursday, February, 25th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.30) by $0.04. Personalis had a negative net margin of 45.13% and a negative trailing twelve-month return on equity of 27.53%.
View Personalis' earnings history
.

How has Personalis' stock been impacted by Coronavirus (COVID-19)?

Personalis' stock was trading at $6.02 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, PSNL shares have increased by 268.6% and is now trading at $22.19.
View which stocks have been most impacted by COVID-19
.

What guidance has Personalis issued on next quarter's earnings?

Personalis issued an update on its first quarter 2021 After-Hours earnings guidance on Thursday, February, 25th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $20.3-20.3 million, compared to the consensus revenue estimate of $20.13 million.

What price target have analysts set for PSNL?

9 Wall Street analysts have issued 12-month target prices for Personalis' shares. Their forecasts range from $24.00 to $50.00. On average, they expect Personalis' stock price to reach $40.56 in the next twelve months. This suggests a possible upside of 82.8% from the stock's current price.
View analysts' price targets for Personalis
or view top-rated stocks among Wall Street analysts.

Who are Personalis' key executives?

Personalis' management team includes the following people:
  • Mr. John Stephen West, Co-Founder, CEO, Pres & Director (Age 64, Pay $785.44k)
  • Mr. Aaron L. Tachibana, Chief Financial Officer (Age 60, Pay $494.4k)
  • Dr. Richard Chen M.S., M.D., MS, Chief Scientific Officer (Age 50, Pay $543.75k)
  • Prof. Russ B. Altman, Co-Founder and Member of Clinical & Scientific Advisory Board
  • Dr. Euan A. Ashley M.D., Ph.D., FRCP, DPHIL, Co-Founder and Member of Clinical & Scientific Advisory Board
  • Dr. Atul Butte, Co-Founder and Member of Clinical & Scientific Advisory Board
  • Dr. Michael Snyder Ph.D., Co-Founder and Member of Clinical & Scientific Advisory Board
  • Ms. Carol J. Tillis, VP of Fin. & Admin.
  • Mr. Stephen M. Moore J.D., Gen. Counsel
  • Mr. Michael J. Fitzpatrick, VP of Worldwide Sales

What is John West's approval rating as Personalis' CEO?

17 employees have rated Personalis CEO John West on Glassdoor.com. John West has an approval rating of 75% among Personalis' employees.

Who are some of Personalis' key competitors?

What other stocks do shareholders of Personalis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Personalis investors own include Enphase Energy (ENPH), Pfizer (PFE), Dynavax Technologies (DVAX), QUALCOMM (QCOM), Advanced Micro Devices (AMD), NIO (NIO), NVIDIA (NVDA), Viking Therapeutics (VKTX), AbbVie (ABBV) and (APHA).

When did Personalis IPO?

(PSNL) raised $100 million in an initial public offering on Thursday, June 20th 2019. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, BofA Merrill Lynch and Cowen and Company acted as the underwriters for the IPO and Oppenheimer was co-manager.

What is Personalis' stock symbol?

Personalis trades on the NASDAQ under the ticker symbol "PSNL."

How do I buy shares of Personalis?

Shares of PSNL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Personalis' stock price today?

One share of PSNL stock can currently be purchased for approximately $22.19.

How much money does Personalis make?

Personalis has a market capitalization of $971.26 million and generates $65.21 million in revenue each year. The company earns $-25,080,000.00 in net income (profit) each year or ($1.39) on an earnings per share basis.

How many employees does Personalis have?

Personalis employs 234 workers across the globe.

What is Personalis' official website?

The official website for Personalis is www.personalis.com.

Where are Personalis' headquarters?

Personalis is headquartered at 1330 O`BRIEN DRIVE, MENLO PARK CA, 94025.

How can I contact Personalis?

Personalis' mailing address is 1330 O`BRIEN DRIVE, MENLO PARK CA, 94025. The company can be reached via phone at 650-752-1300 or via email at [email protected]


This page was last updated on 4/18/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.